Abstracts tagged "Lupus nephritis"

Abstract Number: 639 • 2019 ACR/ARP Annual Meeting
African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup
Michelle Petri¹ and Jessica Li ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: African-Americans lupus nephritis is more common than in Caucasians, more severe and more likely to lead to end stage renal disease. We asked whether…
Abstract Number: 1569 • 2019 ACR/ARP Annual Meeting
Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis
Hironari Hanaoka¹, Jun Kikuchi ², Shuntaro Saito ¹, Hiroshi Takei ³, Kazuoto Hiramoto ¹, Tatsuhiro Oshige ¹, Noriyasu Seki ⁴, Hideto Tsujimoto ⁴, Yuko Kaneko ¹ and Tsutomu Takeuchi ⁵, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Keio Universitiy School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ⁴Mitsubishi Tanabe Pharma Corporation Sohyaku, Tokyo, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Background/Purpose: It has been well investigated that patients with lupus nephritis (LN) have worse prognosis than those without. Recently reported, about 20% of SLE…
Abstract Number: 2567 • 2019 ACR/ARP Annual Meeting
Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates
Tatiana Pedrosa ¹, Sandra G. Pasoto ¹, Emily Yuki², Nadia Aikawa ¹, Eduardo Borba ¹, Julio Ferreira Filho ¹, Pedro Carricondo ³, Caio Zanetti ¹, Paola Conde ¹, Nicole Fontoura ¹, Paschoalina Romano ⁴, Valdemir Carvalho ⁵, Clovis Silva ⁶ and Eloisa Bonfa ⁷, ¹Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., São Paulo, Brazil, ³Ophtalmology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁴Division of Central Laboratory, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁵Fleury Group, Sao Paulo, Brazil, Sao Paulo, Brazil, ⁶Pediatric Rheumatology Unit, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Hydroxychloroquine (HCQ) is the most well established therapy for SLE, as it provides several beneficial properties, such as favorable effects on lipid profile, reduced…
Abstract Number: 653 • 2019 ACR/ARP Annual Meeting
Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis
Kazuoto Hiramoto¹, Hironari Hanaoka ¹, Jun Kikuchi ¹, Shuntaro Saito ¹, Hiroshi Takei ², Tatsuhiro Oshige ¹, Noriyasu Seki ³, Hideto Tsujimoto ³, Yuko Kaneko ¹ and Tsutomu Takeuchi ¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ³Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan
Background/Purpose: Elderly-onset SLE is recognized to be benign disease entity with a favorable nature course. Although late-onset lupus nephritis (LN), long interval between onset of…
Abstract Number: 1733 • 2019 ACR/ARP Annual Meeting
Long-term Renal Survival of Pediatric Onset Lupus Patients in a Population-Based Cohort
Catherine Park ¹, Janet Figueroa ¹, Cristina Drenkard ¹, Laura Plantinga ¹, Larry Greenbaum ² and S Sam Lim¹, ¹Emory University, Atlanta, GA, ²Emory University and Children's Healthcare of Atlanta, Atlanta, GA
Background/Purpose: Compared to adult-onset disease, pediatric-onset SLE (p-SLE) has more severe renal involvement. There are no population-based, long-term follow-up studies of pediatric lupus nephritis (LN)…
Abstract Number: 2568 • 2019 ACR/ARP Annual Meeting
Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study
Qingran Yan¹, Chunde Bao ², Yuening Kang ¹, Qiong Fu ¹ and Ran Wang ¹, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Despite significant advances in the management of patients with lupus nephritis (LN), a significant proportion of patients either do not respond to first-line immunosuppressive…
Abstract Number: 663 • 2019 ACR/ARP Annual Meeting
Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis
Hayam ElAggan¹, Nahla Farahat ¹, Mohamed Sakr ¹ and Shaymaa Tawfik ¹, ¹Faculty of Medicine, University of Alexandria, Alexandria, Egypt, Alexandria, Egypt
Background/Purpose: Toll-like receptor 7 (TLR7) can sense single-stranded RNA with subsequent induction of different interferon (IFN) types including IFN lambda (IFNL) and may contribute to…
Abstract Number: 1735 • 2019 ACR/ARP Annual Meeting
Clinical Variables Influencing Prednisone Dosing Towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis
Nathalie Chalhoub¹, Tingting Qiu ², Jianghong Deng ³, Angela Merritt ², Bin Huang ⁴ and Hermine Brunner ⁴, ¹The University of Cincinnati College of Medicine, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Beijing Children's Hospital, Beijing, China (People's Republic), ⁴Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Corticosteroids (CS) are the mainstay of childhood-onset systemic lupus erythematosus (cSLE) and proliferative lupus nephritis (LN) therapy. However, there are no widely accepted CS…
Abstract Number: 2570 • 2019 ACR/ARP Annual Meeting
Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis
Amira El Gerby ¹, Abeer Abdelati ², Hanaa Donia ³ and Nouran Eshak⁴, ¹Rheumatology Department, Faculty of Medicine, Alexandria University, Egypt, Alexandria, Egypt, ²alexandria university, alexandria, Egypt, ³Clnical and Chemical Pathology Department, Faculty of Medicine, ALexandria University, Alexandria, Egypt, ⁴Rheumatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Lubbock, TX
Background/Purpose: Proliferative lupus nephritis (LN) is one of the most common and serious manifestations of SLE and is a major cause of morbidity. A search…
Abstract Number: 665 • 2019 ACR/ARP Annual Meeting
Utility of Repeat Renal Biopsies in Patients with Lupus Nephritis in Western Australia
Warren Raymond¹, Alexandra Kang ², Daniel Wong ³, Aron Chakera ⁴ and Johannes Nossent ¹, ¹School of Medicine, The University of Western Australia, Crawley, Western Australia, Australia, ²PathWest, Nedlands, Western Australia, Australia, ³PathWest, Perth, Western Australia, Perth, Western Australia, Australia, ⁴Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
Background/Purpose: The role of repeat renal biopsy (RRBx) in lupus nephritis (LN) to guide treatment or predict prognosis is not fully understood. We assessed the…
Abstract Number: 1783 • 2019 ACR/ARP Annual Meeting
Reversible Dysregulation of Renal Circadian Rhythm in Lupus Nephritis
Rakesh Mishra ¹, Ramalingam Bethunaickan ¹, Celine Berthier ², Zhengzi Yi ³, Joshua Strohl ¹, Patricio Huerta ¹, Weijia Zhang ⁴ and Anne Davidson⁵, ¹Feinstein Institute for Medical Research, manhasset, NY, ²University of Michigan, Ann Arbor, MI, ³Mount Sinai School of Medicine, New York, ⁴Mount Sinai School of Medicine, New York, NY, ⁵Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Circadian rhythm is a universal phenomenon that governs homeostasis of overall organism functioning as well as of individual organs. Circadian regulation of homeostatic functions…
Abstract Number: 2735 • 2019 ACR/ARP Annual Meeting
Response Gene to Complement -32 Exerts Proinflammatory and Profibrotic Effects in Immune Complex Gediated Glomerulonephritis
Vinh Nguyen ¹, Alexandru Tatomir ², Horea Rus ³, Cinthia Drachenberg ¹, John Papdimitriou ¹, Tudor Badea ⁴, Irina Luzina ⁵ and Violeta Rus¹, ¹Univ of Maryland Sch of Medicine, Baltimore, MD, ²Univ of Maryland Sch of Medicine, Baltimore, ³Univ of Maryland Sch of Med and VAMHCS, Baltimore, MD, ⁴NIH, NEI, Bethesda, MD, ⁵Univ of Maryland Sch of Med AND VAMHCS, Baltimore
Background/Purpose: Response Gene to Complement (RGC)-32 is a cell cycle regulator widely expressed in normal tissues, multiple tumors and a variety of cell lines. RGC-32…
Abstract Number: 684 • 2019 ACR/ARP Annual Meeting
Clinical Biomarkers at Renal Flare Are Associated with Histologic Changes in Repeat Renal Biopsy in Patients with Biopsy-proven Lupus Nephritis
Min Jung Kim¹, Hajeong Lee ¹, Yeong-Wook Song ¹ and Eun Bong Lee ², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul
Background/Purpose: Renal flares are common during treatment of biopsy-proven lupus nephritis (LN). However, it is unknown whether biopsy should be repeated in the event of…
Abstract Number: 1914 • 2019 ACR/ARP Annual Meeting
Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature
Cristina Arriens¹, Quratul Raja ², Syed Ali Husain ², Bessy George ², Majid Abedi ³, Aviva Jacobs ⁴, Timothy Guyon ⁴, Hemani Wijesuriya ³, Teresa Aberle ⁵, Aikaterini Thanou ⁵, Stan Kamp ⁵, Susan R. Macwana ⁵, Eliza F. Chakravarty ¹, Joan T. Merrill ⁶, Judith James ¹, Robert Terbrueggen ⁴ and Joel Guthridge ¹, ¹Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³DxTerity Diagnostics Inc, Anaheim, CA, ⁴DxTerity Diagnostics Inc, Rancho Dominguez, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The interferon (IFN) signature in SLE is well established, distinguishing lupus patients from healthy controls. Additionally, within lupus patients, higher levels of IFN-responsive gene…
Abstract Number: 2741 • 2019 ACR/ARP Annual Meeting
Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States
Fan Zhang¹, Joseph Mears ¹, ilya Korsunsky ¹, Kevin Wei ², Anna Helena Jonsson ², Deepak Rao ¹, Edy Kim ³, Laura Donlin ⁴, Jill Buyon ⁵, Michelle Petri ⁶, Chaim Putterman ⁷, Thomas Tuschl ⁸, Nir Hacohen ⁹, Betty Diamond ¹⁰, Michael Brenner ¹¹ and Soumya Raychaudhuri ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boton, MA, ⁴Hospital For Special Surgery, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Albert Einstein College of Medicine, New York, NY, ⁸Rockefeller Research Laboratories, New York, ⁹Broad Institute, Cambridge, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹Brigham and Women’s Hospital:, Boston
Background/Purpose: Different autoimmune diseases can co-exist in an individual and share similar genetic associations, autoimmune signaling pathways, and clinical manifestations. However, autoimmune diseases present varied…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.